Navigating The Evolving Landscape of Adalimumab Biosimilars for Inflammatory Disease

Different clinical specialists in the management of inflammatory diseases discuss the role of adalimumab biosimilars in the treatment of their patients.

EP. 1: The Need for Biosimilars in Inflammatory Diseases and Regulatory Requirements for Approval

March 29th 2024

Drs Lio, Botsoglou, and Alexrad discuss the need for biosimilars in inflammatory diseases, and clinical pharmacist Dr Humphreys reviews the regulatory requirements for biosimilars to receive FDA approval.

EP. 2: An Overview of Adalimumab Biosimilars

March 29th 2024

Clinicians and a pharmacist provide an overview of the emerging adalimumab biosimilars in the recent years.

EP. 3: The Pharmacological Aspects of Adalimumab Biosimilars

April 5th 2024

A clinical pharmacist reviews the various pharmacological aspects of the available adalimumab biosimilars.

EP. 4: The Safety and Efficacy of Adalimumab Biosimilars in Inflammatory Diseases

April 5th 2024

Specialists in rheumatology, dermatology and gastrointestinal disease discuss clinical trials that have shown safety and efficacy of adalimumab biosimilars in inflammatory diseases.

EP. 5: Impact of the Launch of Adalimumab Biosimilars in Different Clinical and Pharmacy Settings

April 12th 2024

Experts talk about the impact of the launch of adalimumab biosimilar on their clinical practices and pharmacy.

EP. 6: The Role of Pharmacy Benefit Managers and Payers in Accessing Adalimumab Biosimilars

April 12th 2024

A clinical pharmacist discusses the role of pharmacy benefit managers and payers in accessibility of adalimumab biosimilars.

EP. 7: Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice

April 19th 2024

A clinical pharmacist and specialists in rheumatology, dermatology, and gastrointestinal disease share strategies in how to increase the uptake of adalimumab biosimilar among providers.

EP. 8: Selecting Between Adalimumab Biosimilars for Your Patients

April 19th 2024

Providers in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients.

EP. 9: Switching From Adalimumab to a Biosimilar

April 29th 2024

Specialists in rheumatology, dermatology and gastrointestinal disease discuss the evidence on efficacy and safety on switching patient to an adalimumab biosimilar.

EP. 10: Clinical Experience With Initiating Adalimumab Biosimilars

April 29th 2024

Specialists in rheumatology, dermatology and gastrointestinal disease share their clinical experience on initiating or switching their patients on adalimumab biosimilars.